Compare · SILK vs WST
SILK vs WST
Side-by-side comparison of Silk Road Medical Inc. (SILK) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SILK and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $22.59B, about 21.2x SILK ($1.07B).
- WST has hit the wire 4 times in the past 4 weeks while SILK has been quiet.
- SILK has more recent analyst coverage (25 ratings vs 16 for WST).
- Company
- Silk Road Medical Inc.
- West Pharmaceutical Services Inc.
- Price
- $27.50+0.02%
- $320.02+1.78%
- Market cap
- $1.07B
- $22.59B
- 1M return
- -
- -0.60%
- 1Y return
- -
- +42.97%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 0
- 4
- Recent ratings
- 25
- 16
Silk Road Medical Inc.
Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products includes ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest SILK
- Boston Scientific Announces Results for Third Quarter 2024
- SEC Form 15-12G filed by Silk Road Medical Inc.
- SEC Form EFFECT filed by Silk Road Medical Inc.
- Amendment: SEC Form SC 13D/A filed by Silk Road Medical Inc.
- Director Zurbay Donald returned 12,610 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Weatherman Elizabeth H returned 155,004 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Lasersohn Jack W returned 16,735 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Chou Tony M. returned 85,251 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Carino Tanisha returned 11,396 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Ballinger Kevin J. returned 23,666 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest WST
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)
- Director Lockhart Stephen H was granted 791 shares, increasing direct ownership by 29% to 3,523 units (SEC Form 4)